MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics.
Saved in:
| Title: | MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics. |
|---|---|
| Authors: | Maseda R; Department of Dermatology, La Paz University Hospital, Madrid, Spain., Arriba MC; U714-CIBERER (Centro de Investigación Biomédica en Red de Enfermedades Raras), Madrid, Madrid, Spain.; Department of Bioengineering, Universidad Carlos III de Madrid (UC3M), Madrid, Spain.; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain., Martínez-Santamaría L; U714-CIBERER (Centro de Investigación Biomédica en Red de Enfermedades Raras), Madrid, Madrid, Spain.; Department of Bioengineering, Universidad Carlos III de Madrid (UC3M), Madrid, Spain.; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.; Spanish Network of Advanced Therapies by TERAV-ISCIII, Madrid, Spain., Jiménez E; Cell Biology Department, Faculty of Medicine, Complutense University, Madrid, Spain., Herráiz-Gil S; U714-CIBERER (Centro de Investigación Biomédica en Red de Enfermedades Raras), Madrid, Madrid, Spain.; Department of Bioengineering, Universidad Carlos III de Madrid (UC3M), Madrid, Spain.; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain., Illera N; U714-CIBERER (Centro de Investigación Biomédica en Red de Enfermedades Raras), Madrid, Madrid, Spain.; Department of Bioengineering, Universidad Carlos III de Madrid (UC3M), Madrid, Spain.; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain., Quintana-Castanedo L; Department of Dermatology, La Paz University Hospital, Madrid, Spain., García M; U714-CIBERER (Centro de Investigación Biomédica en Red de Enfermedades Raras), Madrid, Madrid, Spain.; Department of Bioengineering, Universidad Carlos III de Madrid (UC3M), Madrid, Spain.; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.; Spanish Network of Advanced Therapies by TERAV-ISCIII, Madrid, Spain., Suárez-Sancho S; Spanish Network of Advanced Therapies by TERAV-ISCIII, Madrid, Spain.; ATMPs Production Unit-GMP Facility, Gregorio Marañón General University Hospital, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain., Yáñez R; Spanish Network of Advanced Therapies by TERAV-ISCIII, Madrid, Spain.; Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas, Medioambientales, y Tecnológicas (CIEMAT)/Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER-ISCIII), Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain., Pérez-Conde I; Department of Dermatology, La Paz University Hospital, Madrid, Spain., Carretero M; U714-CIBERER (Centro de Investigación Biomédica en Red de Enfermedades Raras), Madrid, Madrid, Spain.; Department of Bioengineering, Universidad Carlos III de Madrid (UC3M), Madrid, Spain.; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.; Spanish Network of Advanced Therapies by TERAV-ISCIII, Madrid, Spain., Martínez-Queipo M; St John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, United Kingdom.; National Institute for Health and Care Research (NIHR) Biomedical Research Centre, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, United Kingdom., de Paz R; IdiPAZ, Hospital La Paz Insititute for Health Research, La Paz University Hospital, Madrid, Spain., León C; U714-CIBERER (Centro de Investigación Biomédica en Red de Enfermedades Raras), Madrid, Madrid, Spain.; Department of Bioengineering, Universidad Carlos III de Madrid (UC3M), Madrid, Spain.; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.; Spanish Network of Advanced Therapies by TERAV-ISCIII, Madrid, Spain., Jiménez-Yuste V; Coagulopathies and Haemostasis Disorders Group, IdiPaz, Hematology and Haemotherapy Unit, La Paz University Hospital, Madrid, Spain., Borobia AM; Clinical Pharmacology Department, IdiPAZ, La Paz University Hospital, School of Medicine, Autonomous University of Madrid, Madrid, Spain., Vicente Á; Spanish Network of Advanced Therapies by TERAV-ISCIII, Madrid, Spain.; Cell Biology Department, Faculty of Medicine, Complutense University, Madrid, Spain.; Stem Cells, Immunity and Cancer Group, Health Research Institute Hospital 12 de Octubre (i+ 12), Madrid, Spain., Lwin SM; St John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, United Kingdom.; National Institute for Health and Care Research (NIHR) Biomedical Research Centre, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, United Kingdom., McGrath JA; St John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, United Kingdom.; National Institute for Health and Care Research (NIHR) Biomedical Research Centre, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, United Kingdom., Fernández-Santos ME; Spanish Network of Advanced Therapies by TERAV-ISCIII, Madrid, Spain.; ATMPs Production Unit-GMP Facility, Gregorio Marañón General University Hospital, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain., Butta N; Coagulopathies and Haemostasis Disorders Group, IdiPaz, Hematology and Haemotherapy Unit, La Paz University Hospital, Madrid, Spain., Sacedón R; Spanish Network of Advanced Therapies by TERAV-ISCIII, Madrid, Spain.; Cell Biology Department, Faculty of Medicine, Complutense University, Madrid, Spain., Del Río M; U714-CIBERER (Centro de Investigación Biomédica en Red de Enfermedades Raras), Madrid, Madrid, Spain.; Department of Bioengineering, Universidad Carlos III de Madrid (UC3M), Madrid, Spain.; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.; Spanish Network of Advanced Therapies by TERAV-ISCIII, Madrid, Spain., de Lucas R; Department of Dermatology, La Paz University Hospital, Madrid, Spain., Escámez MJ; U714-CIBERER (Centro de Investigación Biomédica en Red de Enfermedades Raras), Madrid, Madrid, Spain.; Department of Bioengineering, Universidad Carlos III de Madrid (UC3M), Madrid, Spain.; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.; Spanish Network of Advanced Therapies by TERAV-ISCIII, Madrid, Spain. |
| Source: | Frontiers in immunology [Front Immunol] 2026 May 05; Vol. 17, pp. 1789537. Date of Electronic Publication: 2026 May 05 (Print Publication: 2026). |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II; Clinical Trial |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2026.1789537 |
